Brief: Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
02/02/2026 12:24
Feb 2 (Reuters) - Sagimet Biosciences Inc SGMT.O: SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS’ OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) TABLETS IN PATIENTS WITH MODERATE TO SEVERE ACNE SAGIMET BIOSCIENCES INC - DENIFANSTAT WELL TOLERATED WITH TEAES INCIDENCE RATE OF 5% OR MORE SAGIMET BIOSCIENCES INC - DENIFANSTAT SHOWS IMPROVEMENTS IN EFFICACY ENDPOINTS BEYOND 12 WEEKS Source text: ID:nGNXBnQp7 Further company coverage: SGMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage